NICE new medicines' evidence summary: Lixisenatide for type 2 diabetes

Source: NICE Area: Evidence > Drug Specific Reviews These evidence summaries are provided to help commissioners, budget holders and groups such as Area Prescribing Committees to make informed decisions and aid local planning on the introduction of key new medicines. They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, that are considered to be of significance to the NHS. The topics selected are medicines that have recently gone into the UK market, or medicines that may be marketed in the UK in the next 6-12 months. The strengths and weaknesses of the relevant evidence are critically reviewed.   The subject of this summary is the use of lixisenatide, a glucagon-like peptide-1 (GLP-1) mimetic for use in combination with basal insulin or oral antidiabetic drugs for treating type 2 diabetes in adults whose blood glucose is not adequately controlled on these treatments alone. It is administered by injection once daily. The ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news